As of October 6, 2023, Amgen officially acquired Horizon Therapeutics. For our cystinosis community using PROCYSBI as a therapeutic...
Read moreBy Cystinosis Research Network
November 6, 2023
The long awaited Cystinosis Advocate Newsletter is here. Choose from research updates, advocacy efforts, family stories, events, cystinosis support...
Read moreBy Cystinosis Research Network
November 6, 2023
In May 2023, Novartis acquired the investigational autologous hematopoietic stem cell (HSC) gene therapy program for the treatment of...
Read moreBy Cystinosis Research Network
October 27, 2023
A newly approved eye drop solution will expand treatment options for people living with cystinosis in Canada. Targeting corneal...
Read moreThe Cystinosis Research Network (CRN) is pleased to welcome two newly appointed leaders whose professional expertise, lived experience, and...
Read moreNews from Leadiant regarding new storage of Cystaran (cysteamine ophthalmic solution) 0.44%. Beginning December 22, 2025, shipments of Cystaran...
Read moreThe next phase of clinical development for the CF10 prodrug to treat cystinosis has been announced. The Cystinosis Foundation...
Read moreThe Neuromuscular Clinic at Massachusetts General Hospital (MGH) led by Dr. Reza Seyedsadjadi, is currently enrolling participants for a...
Read moreEmory University in Atlanta, Georgia, is actively recruiting for the Cohort 0 control groupin the CYStem clinical trial. While...
Read more